ARPO - エアピオ・ファ―マシュ―ティカルズ （Aerpio Pharmaceuticals Inc.） エアピオ・ファ―マシュ―ティカルズARPOのチャート
ARPOの企業情報
| symbol | ARPO |
|---|---|
| 会社名 | Aerpio Pharmaceuticals Inc （エアピオ・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Aerpio Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on developing treatments for ocular disease. Its lead product candidate is AKB-9778. Its other two pipeline programs include AKB-4924 and ARP-1536. AKB-9778 is a small molecule activator of the Tie-2 pathway which is being developed for the treatment of diabetic retinopathy (DR). AKB-4924 is a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha) which is being developed for the treatment of inflammatory bowel disease (IBD). ARP-1536 is a humanized monoclonal antibody directed at the same target as AKB-9778. ARP-1536 binds the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP) inhibiting its ability to interact with Tie-2. As of April 14 2017 the Company had completed a Phase II trial of AKB-9778 in 144 patients with diabetic macular edema. As of April 14 2017 the Company had completed Phase Ia clinical trial in healthy volunteers for AKB-4924. エアピオ・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。主に眼疾患の治療薬の開発に注力する。主要パイプラインのAKB-9778は、血管透過性制御に関わるTie2シグナル伝達経路により糖尿病網膜症の治療に有効。また、加齢黄斑変性症や糖尿病性黄斑浮腫の治療薬ARP-1536や、炎症性腸疾患のためのAKB-4924がある。本社所在地はオハイオ州シンシナティ。 Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing compounds that activate Tie2 for indications in which the Company believes that activation of Tie2 may have therapeutic potential. The Company's lead compound, razuprotafib (formerly AKB-9778), a first-in-class small molecule inhibitor of vascular endothelial protein tyrosine phosphatase ("VE-PTP"). The Company is also evaluating development options for ARP-1536, a humanized monoclonal antibody, for its therapeutic potential in the treatment of diabetic vascular complications including nephropathy and diabetic macular edema ("DME"). The Company's third asset is a bispecific antibody that binds both VEGF and VE-PTP which is designed to inhibit VEGF activation and activate Tie2. This bispecific antibody has the potential to be an improved treatment for wet age-related macular degeneration and DME via intravitreal injection. Finally, the Company has exclusively out-licensed AKB-4924 (now called GB004), a first-in-class small molecule inhibitor of hypoxia-inducible factor-1 (HIF). GB004 is being developed by AKB-4924's exclusive licensor, Gossamer Bio, Inc.. In January 2021, the Company announced that it had initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value from the Company's clinical assets and cash resources. |
| 本社所在地 | 9987 Carver Road Cincinnati OH 45242 USA |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | +1 513-985-1920 |
| 設立年月日 | 39387 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 25人 |
| url | www.aerpio.com |
| nasdaq_url | https://www.nasdaq.com/symbol/arpo |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -24.51039 |
| 終値（lastsale） | 3.05 |
| 時価総額（marketcap） | 123768563.85 |
| 時価総額 | 時価総額（百万ドル） 113.62360 |
| 売上高 | 売上高（百万ドル） 1.33333 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 44.84039 |
| 当期純利益 | 当期純利益（百万ドル） -24.30012 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Aerpio Pharmaceuticals Inc revenues increased from $0K to $1.3M. Net loss applicable to common stockholders increased 17% to $13.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research_Development - Balancing value increase of 54% to $8.1M (expense). |
ARPOのテクニカル分析
ARPOのニュース
Aadi Bioscience closes merger with Aerpio Pharmaceuticals and $155M private placement 2021/08/26 20:26:24 Seeking Alpha
Aadi Bioscience Announces Closing of Merger with Aerpio Pharmaceuticals and $155M Private Placement 2021/08/26 20:05:00 Intrado Digital Media
LOS ANGELES, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Aadi) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the closing of its previously announced merger with Aerpio Pharmaceuticals, Inc. (previously traded on the Nasdaq Capital Market under ARPO).
What Do Analysts Recommend? Baudax Bio, Inc. (NASDAQ:BXRX), Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO) 2021/08/24 22:26:15 Stock Equity
Baudax Bio, Inc. (NASDAQ:BXRX) with the stream of 15.90% also noticed, India Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO) encountered a rapid change of -0.45% in the last hour of Tuesdays trading session. The post What Do Analysts Recommend? Baudax Bio, Inc. (NASDAQ:BXRX), Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO) appeared first on Stocks Equity .
Small Cap Alert: Evofem Biosciences, Inc. (NASDAQ:EVFM), Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO) 2021/08/22 21:25:06 Stock Equity
Evofem Biosciences, Inc. (EVFM) with the stream of 1.39% also noticed, India Aerpio Pharmaceuticals, Inc. (ARPO) encountered a rapid change of -0.23% in the last hour of Fridays trading session. The post Small Cap Alert: Evofem Biosciences, Inc. (NASDAQ:EVFM), Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO) appeared first on Stocks Equity .
''Big Short'' investor Michael Burry is betting against Elon Musk and Cathie Wood. Here''s what he bought and sold in Q2. 2021/08/18 12:05:12 Business Insider Markets
Summary List Placement Michael Burry bet against Cathie Wood , increased his wager against Elon Musk, and unexpectedly invested in a technology SPAC in the second quarter, a portfolio update revealed this week . He also switched out most of his holdings, dumping the likes of Occidental Petroleum and Meredith for Discovery and Walmart. Burry''s Scion Asset Management purchased bearish put options on 235,500 shares of Ark Innovation ETF, Wood''s flagship exchange-traded fund. The position signals that Burry is deeply skeptical of the ETF''s holdings, which include Tesla, Coinbase, and Zoom. Scion disclosed puts on about 1.1 million Tesla shares up 34% from around 800,000 shares at the end of March. The increase suggests Burry is more convinced than ever that Musk''s electric-vehicle company is hugely overvalued, and its stock is bound to crash. Notably, Burry''s hedge fund revealed a stake in Vy Global Growth, a blank-check company that went public last year with the goal of acquiring a technology business.